Trial · NCT04855136
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
NCT04855136, Phase 1, Terminated, Celgene
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma. Trials, record NCT04855136. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04855136
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
- NCT number
- NCT04855136
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 21 participants, actual
- Lead sponsor
- Celgene
- Conditions
- Multiple Myeloma
- Interventions
- BB2121, CC-220, BMS-986405
- First posted
- 2021-04-22
- Last updated
- 2026-07-09
- Other registries' IDs
- eudract:2020-003248-10
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Does Limiting Toxicity (DLT) rates _Phase 1 | Up to 28 days from start of the combination therapy | Percentage of participants experiencing DLTs |
| Primary | Complete Response Rate (CRR)_ Phase 2 | Up to 24 months | Proportion of participants who achieved CR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed by investigator's review |
| Secondary | Incidence of Adverse Event (AEs) | Up to 24 months after the last participant received any study treatment | An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. |
| Secondary | Overall Response Rate (ORR) | Up to 24 months after the last participant received any study treatment in the respective cohort | Proportion of participants who achieved PR or better according to IMWG Uniform Response Criteria for Multiple Myeloma as assessed investigator's review |
| Secondary | Progression-free Survival (PFS) | Up to 24 months after the last participant received any study treatment in the respective cohort | Time from first study treatment (whichever is given earlier) start date to the date of either first observation of progressive disease or death due to any cause |
| Secondary | Overall Survival (OS) | Up to 24 months after the last participant received any study treatment in the respective cohort | Time from first study treatment (whichever is given earlier) start date to death due to any cause |
| Secondary | Time to response (TTR) | Up to 24 months after the last participant received any study treatment in the respective cohort | Time from first study treatment start date to the first date of documented response (PR or better) |
| Secondary | Duration of Response (DoR) | Up to 24 months after the last participant received any study treatment in the respective cohort | Time from first documentation of response (PR or better) to first documentation of PD or death due to any cause |
| Secondary | Time to next antimyeloma treatment (TTNT) | Up to 24 months after the last participant received any study treatment in the respective cohort | Time from first study treatment (whichever is given earlier) start date to first day when participant receives another antimyeloma treatment |
| Secondary | Progression-free survival after next antimyeloma therapy (PFS2) | Up to 24 months after the last participant received any study treatment in the respective cohort | Time from first study treatment (whichever is given earlier) start date to documentation of PD on the next-line treatment or death from any cause, whichever is first. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04855136
GET https://conductscience.org/api/trials/v1/NCT04855136/registered